BSSP
The Company as of 2021 is now in process of seeking a merger or acquisition candidate and working to bring the Company current. Effective October 9, 2017 the PSA Agreement with Canteck Pharma, inc. was rescinded do inability to proceed with the license for Mexico that previously had focused on its immunotherapeutic based technology specific to Cancer indication.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2015 Q3 | -0.00 | $0 | -$14,019 |
| 2015 Q2 | -0.01 | $0 | -$44,484 |
| 2015 Q1 | -0.00 | $0 | -$95,175 |
| 2014 Q4 | -0.01 | $0 | -$55,790 |
| 2014 Q3 | -0.00 | $0 | -$43,747 |
| 2014 Q2 | -0.00 | $0 | -$50,316 |
| 2014 Q1 | -0.00 | $0 | -$31,519 |
| 2013 Q4 | -0.00 | $0 | -$24,553 |